Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis

European Journal of Haematology

Volumn 87, Issue 1, 2011, Pages 54-60

  Skov, Vibe ^a   Larsen, Thomas Stauffer ^a   Thomassen, Mads ^a   Riley, Caroline Hasselbalch ^b   Jensen, Morten K ^b   Bjerrum, Ole Weis ^b   Kruse, Torben A ^a   Hasselbalch, Hans Carl ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Essential thrombocythemia; IFI27; Interferon induced genes; Polycythemia vera; Primary myelofibrosis

Indexed keywords

ALPHA2 INTERFERON; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INTERFERON INDUCIBLE GENE 27; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTHEMIA; TUMOR VOLUME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RNA; THROMBOCYTHEMIA, ESSENTIAL; UP-REGULATION;

EID: 79959496299     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01618.x     Document Type: Article

References (59)

1. Tefferi A. The chronic myeloproliferative disorders. Semin Hematol 1999;36(Suppl 2):3-8.
2. Campbell PJ, Green AR. Mechanisms of disease. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.
3. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in postpolycythemia vera myelofibrosis. Blood 2008;111:3383-7.
4. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
6. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
7. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytosis, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
9. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
10. Delhommeau F, Dupont S, Dell Valle V, et al. TET2 mutations in myeloid cancers. N Engl J Med 2009; 360:2289-301.
11. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-6.
12. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38.
13. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010;116:862-4.
14. Finazzi G, Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
15. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
16. Barbui T, Finazzi G. Evidence-based management of polycythemia vera. Best Pract Res Clin Haematol 2006;19:483-93.
17. Finazzi G, Barbui T. How I treat polycythemia vera. Blood 2007;109:5104-11.
18. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leukemia Lymphoma 1996;22(Suppl 1):135-42.
19. Reilly JT, Vellenga E, De Wolff THM. Interferon treatment in polycythaemia vera. Leukemia Lymphoma 1996;22(Suppl 1):143-8.
20. Bachleitner-Hofmann T, Gisslinger H. The role of interferon alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 1999;78:533-8.
21. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy or patients with Philadelphia chromosome negative myeloproliferative disorders. Sem Thromb Hemostas 2006;32:409-14.
22. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 2006;107:451-8.
23. Samuelsson J, Hasselbalch H, Bruserod O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006;106:2397-405.
24. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a phase 2 study. Cancer 2007;110:2012-6.
25. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008;22:1990-8.
26. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Pegylated interferon-alfa-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24.
27. Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, Andersen MT, Bjerrrum OW, Hasselbalch HC. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology 2009;14:331-4.
28. Pellagatti A, Vetrie D, Langford CF, Gama S, Eagleton H, Wainscoat JS, Boultwood J. Gene expression profiling in polycythemia vera using cDNA microarray technology. Cancer Res 2003;63:3940-4.
29. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol 2005;129:138-50.
30. Jones LC, Tefferi A, Vuong PT, Desmond JC, Hofmann WK, Koeffler HP. Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays. Stem Cells 2005;23:631-7.
31. Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, Passamonti F, Pietra D, Cazzola M, Skoda RC. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 2005;106:3374-6.
32. Guglielmelli P, Zini R, Bogani C, et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells 2007;25:165-73.
33. Puigdecanet E, Espinet B, Lozano JJ, et al. Gene expression profiling distinguishes JAK2V617F-negative from JAK2V617F-positive patients in essential thrombocythemia. Leukemia 2008;22:1368-76.
34. Catani L, Zini R, Sollazzo D, Ottaviani E, Vannucchi AM, Ferrari S, Baccarani M, Vianelli N, Lemoli RM, Manfredini R. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia 2009;23:997-1000.
35. Slezak S, Jin P, Caruccio L, et al. Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med 2009;7:39.
36. Berkofsky-Fessler W, Buzzai M, Kim MK, et al. Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clin Cancer Res 2010;16:4339-52.
37. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
38. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
39. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1-26.
40. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Statist Soc B 1995;57:289-300.
41. Rasmussen UB, Wolf C, Mattei MG, Chenard MP, Bellocq JP, Chambon P, Rio MC, Basset P. Identification of a new interferon a-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res 1993;53:4096-101.
42. Gjermandsen IM, Justesen J, Martensen PM. The interferon-induced gene ISG12 is regulated by various cytokines as the gene 6-16 in human cell lines. Cytokine 2000;12:233-8.
43. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon alpha-inducible protein 27 (IFI27) is upregulated in psoriatric skin and certain epithelial cancers. J Invest Dermatol 2004;122:717-62.
44. Kaporis HG, Guttman-Yassky E, Lowes MA, et al. Human basal cell carcinoma is associated with Foxp3 T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007;127:2391-8.
45. Mengwasser J, Mink S. Confirmation of differentially expressed genes in normal and tumor tissues using clontech cancer profiling assays. Clontechniques 2003;XVIII:12-3.
46. Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361:1590-7.
47. Nishia M, Tomita Y, Nakatsuka S, et al. Distinct pattern of gene expression in pyothorax-associtaed lymphoma (PAL), a lymphoma developing in long-standing inflammation. Cancer Sci 2004;95:828-34.
48. Hasselbalch HC. Myelofibrosis with myeloid metaplasia. The advanced phase of an untreated disseminated haematological cancer. Time to change our therapeutic attitude with early up-front treatment at the time of diagnosis. Leuk Res 2009;33:11-8.
49. Kristinsson SY, Landgren O, Samuelsson S, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica 2010;95:1216-20.
50. Hasselbalch H, Jans H, Nielsen PL. A distinct subtype of idiopathic myelofibrosis with bone marrow features mimicking hairy cell leukemia: evidence of an autoimmune pathogenesis. Am J Hematol 1987;25:225-9.
51. Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis. A steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore) 1994;73:145-52.
52. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003;100:2610-5.
53. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
54. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003;36:481-90.
55. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
56. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004;16:801-7.
57. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19:1012-9.
58. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in haematological patients. Acta Haematol 2002;107:133-44.
59. Dunn PG, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.